Hypofractionated Proton Therapy in Early Prostate Cancer: Results of a Phase I/II Trial at Loma Linda University
Authors:
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in International Journal of Particle Therapy
- Vol. 6 (1) , 1-9
Abstract
To determine whether a hypofractionated proton therapy regimen will control early-stage disease and maintain low rates of side effects similar to results obtained using standard-fraction proton therapy at our institution. A cohort of 146 patients with low-risk prostate cancer according to National Comprehensive Cancer Network guidelines (Gleason score <7, prostate-specific antigen [PSA] <10, tumor stage of T1-T2a) received 60 Gy (cobalt Gy equivalent) of proton therapy (20 fractions of 3.0 Gy per fraction) in 4 weeks, a dose biologically equivalent to standard fractionation (44-45 fractions of 1.8 Gy to a total of 79.2 to 81 Gy in 0 weeks). Patients were evaluated at least weekly during treatment, at which time documentation of treatment tolerance and acute reactions was obtained. Follow-up visits were conducted every 3 months for the first 1 years, every 6 months for the next 3 years, then annually. Follow-up visits consisted of history and physical examination, PSA measurements, and evaluation of toxicity. The median follow-up time was 42 months (range, 3-96 months). Acute grade 2 urinary toxicity occurred in 16% (20/120) of the patients; acute grade 2 or higher gastrointestinal toxicity was seen in 1.7% (2/120). At 9 months, 1 patient had late grade 3 urinary toxicity, which resolved by 12 months; no grade 3 gastrointestinal toxicities occurred. The 3-year biochemical survival rate was 99.3% (144/145). The median time to PSA nadir was 30 months. Hypofractionated proton therapy of 60 Gy in 20 fractions was safe and effective for patients with low-risk prostate cancer.Keywords
This publication has 18 references indexed in Scilit:
- Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- The Long-term Disease-specific Mortality of Low-risk Localized Prostate Cancer: A Prospective Population-based Register Study Over Two DecadesUrology, 2016
- Partial Breast Radiation Therapy With Proton Beam: 5-Year Results With Cosmetic OutcomesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Five-Year Outcomes from 3 Prospective Trials of Image-Guided Proton Therapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- High-Dose Hypofractionated Proton Beam Radiation Therapy Is Safe and Effective for Central and Peripheral Early-Stage Non-Small Cell Lung Cancer: Results of a 12-Year Experience at Loma Linda University Medical CenterInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppressionActa Oncologica, 2013
- Early Outcomes From Three Prospective Trials of Image-Guided Proton Therapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- The radiobiology of prostate cancer including new aspects of fractionated radiotherapyActa Oncologica, 2005
- Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons aloneInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995